Article
BRD4-mediated repression of p53 is a target for combination therapy in AML
2020-09-16
Abstract excerpt
<h4>Summary</h4> Acute Myeloid Leukemia (AML) is a typically-lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53 , encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which activate wild-type p53, and BET inhibitors (BETi), targeting the BET-family co-activator BRD4, both show encouraging pre-clinical activity, but...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 10ffca6a-01b6-5fe2-bdf7-8265ffdce1b2
- DOI
- 10.1101/2020.09.16.291930